secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001213900-25-103780
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex updates on Phase 2 results for IHL-42X and PSX-001; ATM shares unchanged since Aug 2025
--------------------------------------------------------------------------------

- IHL-42X Phase 2 OSA trial showed up to 83% reduction in AHI; 57.6% of participants reported improvement (78.6% low dose).
- PSX-001 Phase 2 GAD trial met primary endpoint HAM-A and multiple secondary measures with sustained relief over 11 weeks, no SAEs.
- ATM facility not utilized since Aug 28, 2025; total shares outstanding unchanged at 347,705,507.
- Company prioritizing FDA engagement for pivotal development of IHL-42X and PSX-001, and exploring partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025103780/0001213900-25-103780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025103780/ea0262765-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-103780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer